百克生物 (688276.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−36.9x

Market Cap

CNY 6.71B

MomentumView details →

1D Return

−6.57%

YTD Return

—

RSI (14)

49.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−36.9x

Market Cap

CNY 6.71B

RSI (14)

49.1

MomentumView details →

1D Return

−6.57%

YTD Return

—

ProfitabilityView details →

Gross Margin

72.06%

Net Margin

−45.26%

EBITDA Margin

−30.88%

ROE (TTM)

−6.95%

ROA (TTM)

−5.21%

Asset Turnover

0.12x

GrowthView details →

Revenue YoY

−47.36%

EPS YoY

—

FCF YoY

+51.11%

Revenue CAGR 3Y

−17.34%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.12

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.08x

Current Ratio

1.28x

Quick Ratio

1.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

+12.67%

Financials snapshotView financials →

Revenue (TTM)

590.13M

Net Income (TTM)

−267.12M

Op. CF (TTM)

318.70M

Next earningsOct 26, 2026 →

Latest newsMore news →

Baike Biological announced its 2026 first-half results: net loss attributable to shareholders narrowed to 52.1001 million yuan from 73.5734 million yuan a year earlier, with revenue up 6.89% to 305 million yuan.16d ago

Similar companies

康缘药业600557.SH China Traditional Chinese Medicine Holdings Co. Limited00570.HK Lantheus Holdings, Inc.LNTH 亚虹医药-U688176.SH 中牧股份600195.SH 中恒集团600252.SH Find similar companies →

Latest newsMore news →

Baike Biological announced its 2026 first-half results: net loss attributable to shareholders narrowed to 52.1001 million yuan from 73.5734 million yuan a year earlier, with revenue up 6.89% to 305 million yuan.16d ago